From a prostate cancer combo that uses your tumor's own broken DNA-repair against it, to the first drug ever to succeed in a rare autoimmune disease called IgG4-related disease — Part 2 of our weekly biomedicine recap covers three more major readouts from the week of May 30 – June 5, 2026. In Part 2 we cover:

4. Pfizer — Talazoparib plus enzalutamide for metastatic castration-sensitive prostate cancer with DNA-repair mutations (Phase 3)

5. Zenas BioPharma — Obexelimab for IgG4-related disease (Phase 3)

6. Karyopharm Therapeutics — Selinexor plus ruxolitinib for myelofibrosis (Phase 3)

The IgG4-RD result may be the most quietly historic of the week: IgG4-related disease is a rare autoimmune condition where misbehaving B cells form fibrotic masses in organs throughout the body, and there has never been an approved therapy — patients rely on steroids long-term. Obexelimab, a clever 'bifunctional' antibody that calms B cells without killing them, cut the risk of disease flare by 56% in a 52-week Phase 3 trial — the first positive Phase 3 ever in this disease, published in the New England Journal of Medicine. We explain what makes the antibody design unusual and why a positive trial here could change rare-disease drug development more broadly.

Catch Part 1 if you missed it. Subscribe at TrialBreaks.com

#oncology #prostatecancer #PARPinhibitor #autoimmune #IgG4 #rheumatology #rarediseases #myelofibrosis #hematology #targetedtherapy #precisionmedicine #biomedicine #clinicaltrials #science

The biggest week in cancer research of 2026 dropped at the ASCO meeting in Chicago, and one drug stole the show: a new RAS-blocking pill that nearly doubled survival in metastatic pancreatic cancer, one of the deadliest diseases in medicine. In Part 1 we cover:

1. Revolution Medicines — Daraxonrasib for metastatic pancreatic cancer (Phase 3)
2. Summit Therapeutics and Akeso — Ivonescimab for first-line squamous non-small cell lung cancer (Phase 3)
3. Eli Lilly — Selpercatinib for adjuvant RET fusion-positive non-small cell lung cancer (Phase 3)
Daraxonrasib targets RAS, the 'on switch' that drives roughly a third of all cancers and almost every pancreatic tumor. Unlike earlier RAS drugs that hit only one specific mutation, daraxonrasib blocks the active form of multiple RAS variants at once — and the result was a near-doubling of median overallsurvival from 6.6 months to 13.2 months in patients who had already failed first-line chemo. Doctors at the ASCO Plenary called the data 'transformative' and gave a standing ovation. We break down the science, explain why pancreatic cancer has been so untreatable, and walk through what RAS-ON inhibitors could mean for other tumors in the years ahead.
Part 2 drops Thursday morning. Subscribe at TrialBreaks.com
#oncology #pancreaticcancer #lungcancer #precisionmedicine #RAS #immunotherapy #bispecificantibody #PD1 #targetedtherapy #ASCO2026 #biomedicine #clinicaltrials #science

In Part 2 we cover the remaining clinical trial readouts from the week of May 23–29, 2026 — a Phase 2 atopic dermatitis breakthrough and a Phase 3 multiple sclerosis convenience win.
4. Apogee Therapeutics — Zumilokibart for Moderate-to-Severe Atopic Dermatitis (Phase 2)
5. TG Therapeutics — BRIUMVI (ublituximab-xiiy) for Relapsing Forms of Multiple Sclerosis (Phase 3 ENHANCE)
Apogee Therapeutics delivered a strong Phase 2 result in moderate-to-severe atopic dermatitis — 65.9% of mid-dose patients achieved a 75% reduction in disease severity at 16 weeks, compared with 23.4% on placebo. TG Therapeuticsshowed that a single Day-1 infusion of BRIUMVI gives the same drug exposure as the current two-dose initiation, simplifying multiple sclerosis treatment for thousands of patients.
Catch Part 1 if you missed it. Subscribe at TrialBreaks.com
#dermatology #atopicdermatitis #multiplesclerosis #neurology #biomedicine #clinicaltrials #science #medicalresearch

In Part 1 we cover the three biggest clinical trial readouts from the week of May 23–29, 2026 — including two ASCO 2026 opening-day announcements that reshape oncology.

1. Bristol Myers Squibb — Mezigdomide for Relapsed or Refractory Multiple Myeloma (Phase 3)
2. GSK — Bepirovirsen for Chronic Hepatitis B Infection (Phase 3)
3. Pfizer — LORBRENA (lorlatinib) for ALK-Positive Non-Small-Cell Lung Cancer (Phase 3, 7-year update)
The biggest story: Bristol Myers Squibb's mezigdomide became the first Phase 3 win for the new CELMoD drug class, cutting disease progression risk in half for patients with relapsed or refractory multiple myeloma. The trial showed medianprogression-free survival of 18 months on mezigdomide combination versus 8.3 months on standard of care — a doubling of how long patients stay disease-stable.

Part 2 drops Thursday. Subscribe at TrialBreaks.com

#oncology #multiplemyeloma #lungcancer #hepatitisB #biomedicine #clinicaltrials#science #medicalresearch

Part 2 of our May 18–22, 2026 roundup digs into a first-in-class Bicycle Toxin Conjugate for bladder cancer, a non-surgical DNA immunotherapy clearing HPV-driven cervical pre-cancer, anoff-the-shelf cancer vaccine extending remission in ovarian cancer, an engineered IL-2 antibody pulling responses out of melanoma that had resisted every checkpoint inhibitor, and a topical hair-loss drug that may finally give men a side-effect-light alternative to finasteride.
In Part 2 we cover:6. Bicycle Therapeutics — Zelenectide Pevedotin (BT8009) for Advanced Bladder (Urothelial) Cancer (Phase 2/3)7. ApolloBio (with INOVIO) — VGX-3100 for HPV-16/18 High-Grade Cervical Pre-Cancer (Phase 3)8. OSE Immunotherapeutics — Tedopi for Platinum-Sensitive Recurrent Ovarian Cancer (Phase 2)9. Aulos Bioscience — Imneskibart (AU-007) for Checkpoint-Inhibitor-Refractory Metastatic Melanoma (Phase 2)10. Cosmo Pharmaceuticals — Clascoterone 5% Topical Solution for Male Androgenetic Alopecia (Phase 3)
The Bicycle Therapeutics readout is a fascinating proof-of-concept. Instead of a giant antibody hauling chemo to a tumor, Bicycle uses a tiny constrained peptide as the targeting head — small enough to penetrate solid tumors more deeply and clear from the body faster than a traditional antibody-drugconjugate. Positive Phase 2 data in advanced bladder cancer suggest this 'bicycle' platform could become a new way to deliver targeted chemotherapy across many cancers. We also pull back to identify the big pipeline themes connecting all ten of this week's readouts.
Catch Part 1 if you missed it. Subscribe at TrialBreaks.com
#biomedicine #clinicaltrials #science #oncology #bladdercancer #ovariancancer #melanoma #immunotherapy #HPV #cervicalcancer #dermatology #hairloss #vaccines#drugdiscovery #ADC

This week the biggest story in clinical trial results came out of an obesity trial: Eli Lilly's retatrutide — a once-weekly shot that activates three different appetite-and-metabolism hormones (GIP, GLP-1, and glucagon) at the same time — helped adults with obesity lose an average of roughly 30% of their body weight at 80 weeks. That level of weight loss was previously only seen with bariatric surgery. We also unpack a TROP-2 antibody-drug conjugate from Merck and Kelun-Biotech thatscored back-to-back Phase 3 wins in two tough cancers, plus a novel approach to gout and a new mechanism for stubborn high blood pressure.
In Part 1 we cover:1. Eli Lilly — Retatrutide for Obesity (Phase 3)2. Merck — Sacituzumab Tirumotecan (sac-TMT) for Advanced or Recurrent Endometrial Cancer (Phase 3)3. Kelun-Biotech — Sacituzumab Tirumotecan (sac-TMT) for First-Line Advanced Triple-Negative Breast Cancer (Phase 3)
4. Sobi — Pozdeutinurad for Gout (Phase 3)5. Mineralys Therapeutics — Lorundrostat for Uncontrolled and Resistant Hypertension, Including Patients With Chronic Kidney Disease (Phase 3)
The retatrutide readout matters because obesity affects more than a billion people globally, and an injectable medicine reaching surgery-level weight loss could change how doctors and patients think about treatment — moving it from a'maybe later' option to a frontline tool. The same week's sac-TMT cancer wins point to a new class of 'guided-missile' chemotherapy that homes in on the TROP-2 protein found on many tumors, and the gout and hypertension readoutsboth crack open therapy classes that have been stuck for decades.
Part 2 drops Thursday. Subscribe at TrialBreaks.com#biomedicine #clinicaltrials #science #obesity #GLP1 #oncology #breastcancer #endometrialcancer #ADC #cardiology #hypertension #gout #immunotherapy #drugdiscovery

Top 10 significant clinical trial results from last week

Part 2:

6. Enterprise Therapeutics (private) — ETD001 (inhaled ENaCblocker) for cystic fibrosis (Phase 2)
7. Daré Bioscience ($DARE) — Ovaprene (hormone-free monthly intravaginal contraceptive) for contraception (Phase 3)
8. Candel Therapeutics ($CADL) — aglatimagene besadenovec (CAN-2409) for localized prostate cancer (Phase 3)
9. Alpha Tau Medical ($DRTS) — Alpha DaRT intratumoral alpha-radiotherapy for recurrent glioblastoma (Phase 2)
10. IMUNON ($IMNN) — IMNN-001 (IL-12 plasmid gene therapy) for advanced ovarian cancer (Phase 2)
Subscribe for weekly clinical trial breakdowns at TrialBreaks.com
#biotech #clinicaltrials #pharma #genetherapy #Duchenne #DMD #GLP1 #obesity #oncology #immunotherapy #headandneckcancer #pulmonology #IPF #cysticfibrosis#womenshealth #prostatecancer #glioblastoma #ovariancancer #sleepmedicine

Top 10 significant clinical trial results from last week

Part 1:
1. REGENXBIO ($RGNX) — RGX-202 microdystrophin gene therapy for Duchenne muscular dystrophy (Phase 3)
2. Alkermes ($ALKS) — LUMRYZ (sodium oxybate once-nightly) for idiopathic hypersomnia (Phase 3)
3. Viking Therapeutics ($VKTX) — oral VK2735 (GLP-1/GIP dual agonist) for obesity (Phase 2)
4. Inhibrx Biosciences ($INBX) — INBRX-106 (hexavalent OX40 agonist) plus pembrolizumab for first-line PD-L1+ head and neck squamous cell carcinoma (Phase 2)
5. United Therapeutics ($UTHR) — Tyvaso (inhaled treprostinil) for idiopathic pulmonary fibrosis (Phase 3)

Subscribe for weekly clinical trial breakdowns at TrialBreaks.com
#biotech #clinicaltrials #pharma #genetherapy #Duchenne #DMD #GLP1 #obesity #oncology #immunotherapy #headandneckcancer #pulmonology #IPF #cysticfibrosis#womenshealth #prostatecancer #glioblastoma #ovariancancer #sleepmedicine